NRP1 and neoplasm: Anti-Nrp-1 plus anti-PD-1 combination immunotherapy would allow optimisation of tumour infiltration by CD8+ T cells and CTL reactivity toward target cells thereby improving immune protection and responses to immune checkpoint blockade.